NutropinAq: Withdrawal of the application to change the marketing authorisation

somatropin

Overview

On 24 January 2008, Ipsen Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for NutropinAq, for the long-term treatment of children with severe idiopathic short stature.

  • List item

    Questions and answers on the withdrawal of the application for change to the marketing authorisation for Nutropinaq (PDF/36.8 KB)


    First published: 21/02/2008
    Last updated: 21/02/2008
    EMEA/166909/2008

  • Key facts

    Name
    NutropinAq
    Product number
    EMEA/H/C/000315
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    15/02/2001
    International non-proprietary name (INN) or common name
    • somatropin
    Active substance
    • somatropin
    Date of withdrawal
    24/01/2008
    Company making the application
    Ipsen Pharma
    Withdrawal type
    Post-authorisation

    All documents

    Related content

    Related information on withdrawals

    This text will be replaced by the description of taxonomy term "Template for related information on withdrawals" from vocabulary "String replacement".

    How useful was this page?

    Add your rating